Browse drugs

…84% had received systemic antibiotics in the 12 months prior to fidaxomicin administration, with a median of three courses. The most freque…

…. The median number of prior treatment lines was four. Prior to fruquintinib, 22 patients had received TAS-102 plus bevacizumab, eight recei…

…Auldin MA, Agarwal R, Murray RD. Intramuscular and subcutaneous levothyroxine: a successful treatment for non-compliance. Endocrinol Diabetes…

…These findings extend safety observations beyond semaglutide to tirzepatide. Healthcare providers should consider this potential risk when …

… prescriptions (PIPs) that exceed the maximum recommended dose: omeprazole, esomeprazole and rabeprazole ≥ 40 mg/day, pantoprazole ≥ 80 mg…

…mplications.Conclusion and Relevance In this real-world cohort, axi-cel showed predictable but significant toxicity, including universa…

…ease with highly variable manifestations. New therapies such as belimumab appear to reduce cumulative organ damage and disease flares, im…

… a tapering regimen at 1 mg/Kg/day), tocilizumab (8 mg/kg), and anakinra (200 mg/day). The clinical pharmacist followed the patient thro…

… and barriers in areas of ENBP reported to have highly variable DTP1, DTP3 and measles-rubella first-dose (MR1) coverage.Methods Qua…

…-lowering agents (ezetimibe 4.1%, PCSK9 inhibitor 0.4%, none on bempedoic acid).Conclusions Notable gaps exist in statin prescribing and LDL g…

…cytosis (IFN-γ 62.5%, with inhibitor 27.9%), bacterial killing (IFN-γ 82.1%, with inhibitor 30.5%) and superoxide generation (IFN-γ 2…

… criteria were included; of whom, 121 patients (17.4%) received edoxaban underdosing. At 12 months, the incidence of primary outcome was…